Tenaya Therapeutics/TNYA

$5.84

2.63%
-
1D1W1MYTD1YMAX

About Tenaya Therapeutics

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of disease-modifying therapies that includes both gene therapies and small molecules discovered internally and developed using its product platforms and core capabilities to target defined sub-populations of patients with rare or prevalent forms of heart disease. Its product platforms include Gene Therapy, Cellular Regeneration and Precision Medicine to discover novel therapies for various forms of heart disease. The Company's lead product candidates include, TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy, TN-301, a small molecule for heart failure with preserved ejection fraction, and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).

Ticker

TNYA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Faraz Ali

Employees

141

Headquarters

South san francisco, United States

TNYA Metrics

BasicAdvanced
$401.94M
Market cap
-
P/E ratio
-$1.89
EPS
-
Beta
-
Dividend rate

What the Analysts think about TNYA

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 7 analysts.
227.74% upside
High $40.00
Low $7.00
$5.84
Current price
$19.14
Average price target

TNYA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-29.1M
-12.35%
Profit margin
0%
-

TNYA Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 17.52%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.61
-$0.43
-$0.45
-$0.39
-
Expected
-$0.65
-$0.56
-$0.50
-$0.47
-$0.44
Surprise
-6.15%
-23.67%
-10.6%
-17.52%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Tenaya Therapeutics stock

Buy or sell Tenaya Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing